HIT Expert Probability (HEP) Score
HIT Expert Probability (HEP) score (Cuker 2010): pre-test probability of heparin-induced thrombocytopenia from 8 clinical features weighted by 26 HIT experts. Better interobserver agreement than the 4Ts; use alongside anti-PF4 antibody testing.
Score interpretation
HEP below 2. In the derivation study no HIT case scored below 2 (sensitivity 100%, specificity 60% at a cut-off of 2; Cuker 2010); prospective validation found lower sensitivity, so read it with the 4Ts score.
→ HIT unlikely. Investigate alternative causes of thrombocytopenia. Antibody testing usually not needed if the 4Ts score is also low.
HEP 2–4: HIT cannot be excluded (Pishko 2018: HEP ≥ 3 sensitivity 95%, specificity 36%).
→ Check anti-PF4 antibody (ELISA). Consider switching to non-heparin anticoagulant pending result. Involve haematology.
HEP 5 or more: sensitivity 86%, specificity 88% for HIT (Cuker 2010).
→ Stop all heparin immediately. Switch to argatroban, bivalirudin, or fondaparinux. Send PF4 antibody + confirm with serotonin release assay. Platelet transfusion generally contraindicated.
Interpretation bands for the HEP Score. Apply clinical judgement and local guidance.
References
- Cuker A, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8(12):2642-2650.
- Pishko AM, et al. Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3155-3162.
Related
Curated clinical cross-links plus same-class fallbacks.
- Protamine Sulphate · Heparin Reversal Agent
- Unfractionated Heparin (ACS / PCI) · Anticoagulant / ACS / PCI
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Heparinoid · Topical heparin analogue
- Unfractionated Heparin (IV) · Anticoagulant — ACS / PE / Thrombus
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.